

Special Issue

Cardiovascular Disease in Patients with Familial Hypercholesterolemia

Message from the Guest Editors

Familial hypercholesterolemia (FH) is one of the most common genetic disorders, affecting millions of people worldwide, and is characterized by markedly elevated levels of low-density lipoprotein cholesterol (LDL-C). Left untreated, FH dramatically increases the risk of premature cardiovascular disease (CVD), including heart attacks, strokes, and other atherosclerotic events. This Special Issue on “Cardiovascular Disease in Patients with Familial Hypercholesterolemia” will gather research that addresses the multifaceted challenges posed by FH, from genetic and molecular mechanisms to clinical management and emerging therapies. We invite contributions that explore the latest advancements in diagnostic approaches, risk assessment, therapeutic interventions—including pharmacological and lifestyle treatments—as well as long-term outcomes in FH patients. We look forward to your valuable contributions to this Special Issue.

Guest Editors

Dr. Genovefa D. Kolovou
Prof. Dr. Evangelos Liberopoulos
Prof. Dr. Haralampos J. Milionis

Deadline for manuscript submissions

31 August 2026



Journal of Cardiovascular Development and Disease

an Open Access Journal
by MDPI

Impact Factor 2.3
CiteScore 3.7
Indexed in PubMed



mdpi.com/si/221960

*Journal of Cardiovascular
Development and Disease*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jcdd@mdpi.com

[mdpi.com/journal/
jcdd](https://mdpi.com/journal/jcdd)





Journal of Cardiovascular Development and Disease

an Open Access Journal
by MDPI

Impact Factor 2.3
CiteScore 3.7
Indexed in PubMed



[mdpi.com/journal/
jcdd](https://mdpi.com/journal/jcdd)



About the Journal

Message from the Editor-in-Chief

The primary goal of the *Journal of Cardiovascular Development and Disease (JCDD, ISSN 2308-3425)* is to provide cardiovascular scientists a platform to publish their work in a quick and efficient way. Topics can range from studies designed to decipher the events underlying early heart development to studies focusing on the origins of congenital and acquired heart disease. Papers submitted to *JCDD* undergo a fast, yet thorough, peer-review process. In this process, we will apply strict ethical policies and standards. *JCDD* guarantees fast dissemination of results to a large scientific audience.

Editor-in-Chief

Prof. Dr. Thomas Brand
National Heart & Lung Institute, Imperial College London, South
Kensington Campus, London SW7 2AZ, UK

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Cardiac and Cardiovascular Systems) /
CiteScore - Q2 (General Pharmacology, Toxicology and
Pharmaceutics)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 24.7 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the second half of 2025).